Sign in
Taking people in United StatesPhase 3

ALKS 2680 tablets for daytime sleepiness in adults with narcolepsy type 2

Tests ALKS 2680 against placebo for sleepiness in adults with narcolepsy type 2.

Key facts

Who runs it
Alkermes, Inc.
Where
Austin, Boulder, Brandon, Charlotte, Cincinnati, Columbia, Cullman, Frisco, Huntersville, Kansas City, Lansing, Los Angeles, Macon, Maimi, Newton, Novi, Phoenix, Rochester, San Antonio, Stockbridge, Sugar Land, Winter Park, and Wyomissing, United StatesSee the 23 sitesAlso in 9 other countries, 21 sites
Trial code
Registry title
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Status
Recruiting
Phase
Phase 3
People taking part
176 people, planned
Started
22 Apr 2026
Expected to end
Jun 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • ALKS 2680 Dose 1
  • ALKS 2680 Dose 2
  • ALKS 2680 Dose 3
  • Placebo
Record updated
7 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with narcolepsy type 2 (NT2), a sleep disorder with strong daytime sleepiness. It compares ALKS 2680 tablets with placebo tablets.

Age
18 Years to 70 Years
Sex
All sexes can join
Disease stage
Narcolepsy type 2 as defined by ICSD-3-TR guidelines, confirmed by sleep tests (PSG or MSLT).
Earlier treatment
People treated for obstructive sleep apnea (OSA) must have kept up their main OSA therapy for the 30 days before Visit 1. No investigational drug or device within 30 days before Visit 1. People who were in Study ALKS 2680-202 cannot join.

Main reasons for not taking part

  • Another sleep disorder or condition that may affect the sleep-wake cycle
  • Other serious illness or surgery that could affect safety or the study, in the doctor's view
  • Currently in another interventional clinical trial
  • Taking part in Study ALKS 2680-202 before
  • Pregnant, breastfeeding, or planning a pregnancy during the study

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including the following: lifestyle considerations and restrictions, adherence to contraception guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits
  • Meets the diagnostic criteria of NT2 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG/MSLT)

Who cannot take part

  • Is currently enrolled in another interventional clinical trial or has received any investigational drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-202 are not eligible for enrollment
  • Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle
  • Has a history or presence of other clinically significant (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study
  • Is currently pregnant, breastfeeding, or is planning to become pregnant during the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

Also in 9 other countries, 21 sites

  • Austin, TexasHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Boulder, ColoradoHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Brandon, FloridaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Charlotte, North CarolinaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Cincinnati, OhioHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Columbia, South CarolinaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Cullman, AlabamaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Frisco, TexasHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Huntersville, North CarolinaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Kansas City, KansasHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Lansing, MichiganHospital not named in the registryContact: Director Clinical Trial ManagerNot yet recruiting
  • Los Angeles, CaliforniaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Macon, GeorgiaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Maimi, FloridaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Newton, MassachusettsHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Novi, MichiganHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Phoenix, ArizonaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Rochester, MinnesotaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • San Antonio, TexasHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Stockbridge, GeorgiaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Sugar Land, TexasHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Winter Park, FloridaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people
  • Wyomissing, PennsylvaniaHospital not named in the registryContact: Director Clinical Trial ManagerTaking people

About the trial

What the trial wants to find out

The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.

The 4 groups in the trial

  • ALKS 2680 Dose 1Treatment being tested
  • ALKS 2680 Dose 2Treatment being tested
  • ALKS 2680 Dose 3Treatment being tested
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 (Brilliance NT2 Study 303)
Plain-language title
ALKS 2680 tablets for daytime sleepiness in adults with narcolepsy type 2Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07502443, who can take part
Record updated
7 October 2026